Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates

Company Performance - Insmed reported a quarterly loss of $1.7 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.3, and an improvement from a loss of $1.94 per share a year ago [1][2] - The earnings surprise for this quarter was -30.77%, and the company has not surpassed consensus EPS estimates over the last four quarters [2] - Insmed's revenues for the quarter ended June 2025 were $107.42 million, exceeding the Zacks Consensus Estimate by 3.87%, and up from $90.34 million year-over-year [3] Stock Performance - Insmed shares have increased approximately 61.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [4] - The current Zacks Rank for Insmed is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$1.30 on revenues of $115.44 million, and for the current fiscal year, it is -$5.29 on revenues of $464.32 million [8] - The outlook for the Medical - Biomedical and Genetics industry, where Insmed operates, is currently in the top 41% of over 250 Zacks industries, suggesting a favorable environment for stock performance [9]